<SEC-DOCUMENT>0001144204-16-119768.txt : 20160816
<SEC-HEADER>0001144204-16-119768.hdr.sgml : 20160816
<ACCEPTANCE-DATETIME>20160816160714
ACCESSION NUMBER:		0001144204-16-119768
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160816
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160816
DATE AS OF CHANGE:		20160816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		161836114

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v447151_8-k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
<B>August 16, 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>ABEONA THERAPEUTICS INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 34%; text-decoration: underline; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>Delaware</u></b></font></td>
    <TD STYLE="width: 32%; text-decoration: underline; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>0-9314</u></b></font></td>
    <TD STYLE="width: 34%; text-decoration: underline; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>83-0221517</u></b></font></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation)</font></td>
    <TD STYLE="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</font></td>
    <TD STYLE="text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer Identification No.)</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>3333 Lee Parkway, Suite 600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Dallas, TX 75219</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>(214) 214-665-9495</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.02.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Results of Operations
and Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2016, Abeona Therapeutics
Inc. (&quot;Abeona&quot; or &ldquo;Company&rdquo;) issued a press release reporting the financial results for its fiscal quarter
ended June 30, 2016.&nbsp;A copy of the press release is attached to this Current Report on Form 8-K (&ldquo;Current Report&rdquo;)
as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 2.02 disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in Item 2.02 of this Current
Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &ldquo;filed&rdquo; for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities
of such section.&nbsp;The information in Item 2.02 of this Current Report, including Exhibit 99.1, shall not be incorporated by
reference into any filing under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), or the Exchange Act,
regardless of any incorporation by reference language in any such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements
and</B> <B>Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(d) Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <TD STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-decoration: underline; width: 10%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>Exhibit No.</u></b></font></td>
    <TD STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; width: 1%">&nbsp;</td>
    <TD STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-decoration: underline; width: 89%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>Description</u></b></font></td></tr>
<tr style="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</font></td>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</td>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release dated August 16, 2016, entitled &ldquo;Abeona Therapeutics Announces Second Quarter 2016 Financial Results and Recent Clinical Highlights&rdquo;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Abeona Therapeutics Inc.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%; padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-bottom: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; width: 47%; border-bottom: black 1pt solid; padding-bottom: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">/s/ Stephen B. Thompson </FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Stephen B. Thompson</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Vice President Finance</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 0; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt">Chief&nbsp;Accounting Office </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 16, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Exhibit Number</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; width: 5%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</font></td>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; width: 1%">&nbsp;</td>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify; width: 94%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release dated August 16, 2016, entitled &ldquo;Abeona Therapeutics Announces Second Quarter 2016 Financial Results and Recent Clinical Highlights&rdquo; </font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v447151_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EXHIBIT 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Abeona Therapeutics
Announces Second Quarter 2016 </B><BR>
<B>Financial Results and Recent Clinical Highlights</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>Investor Conference
Call to be held <BR>
Wednesday, August 17<SUP>th</SUP> at 10:00 am ET</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>New York, NY and Cleveland, OH &ndash; August 16, 2016 &ndash;
</B>Abeona Therapeutics Inc. (Nasdaq: ABEO) a clinical-stage biopharmaceutical company focused on delivering gene and plasma-based
therapies for life-threatening rare diseases, today announced financial results for the second quarter. The Company will provide
investors an update on recent and ongoing business activities and an overview of its 2Q16 financials on, Wednesday, August 17<SUP>th</SUP>,
at 10:00 am (Eastern). Interested parties are invited to participate in the call by dialing 877-269-7756 (toll free domestic)
or 201-689-7817 (international). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&quot;The second fiscal quarter of 2016 brought significant
advancements in our goal of building a strong leadership position in the development of innovative therapies for rare diseases,&quot;
stated Steven H. Rouhandeh, Executive Chairman. &quot;We are excited about the initial biopotency signals seen in our Sanfilippo
Type A clinical trial, and are looking forward to advancing multiple important new therapeutic candidates for the treatment of
epidermolysis bullosa (EB), as announced last week. We thank our collaborators, shareholders and staff for their ongoing commitment
and support as we move these therapies further into clinical development.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Timothy J. Miller, Ph.D, stated, &quot;Abeona achieved many
important regulatory and clinical milestones in the second quarter of 2016. The milestones include the dosing of the first patient
in our Phase 1/2 clinical trial with ABO-102 for patients with Sanfilippo syndrome type A, the FDA allowance of our Phase 1/2
clinical study in Sanfilippo syndrome type B (MPS IIIB), and, most recently, the European regulatory approval for our MPS IIIA
Phase 1/2 clinical study to be conducted at Cruces University Hospital in Bilbao, Spain. Additionally, we are excited about our
new collaboration with the EB Research Partnership, EB Medical Research Foundation and Stanford University to accelerate up to
three new promising EB product candidates toward commercialization.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Recent Abeona Operating Highlights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>On May 17, 2016, Abeona announced that the first patient
in its Phase 1/2 trial for ABO-102 (AAV-SGSH), a single treatment gene therapy strategy for patients with Sanfilippo syndrome
type A (MPS IIIA) has been enrolled at Nationwide Children's Hospital in Columbus, Ohio.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>On May 24, 2016, Abeona announced the FDA Allowance of
its Investigational New Drug (IND) for a Phase 1/2 clinical study with ABO-101 (AAV-NAGLU) for patients with Sanfilippo syndrome
type B (MPS IIIB).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>On August 2, 2016, Abeona provided an update on the initial
subjects enrolled in this trial, stating that ABO-102 had been well tolerated with no safety or tolerability concerns identified
through 30-days post-injection, and that encouraging signs of early biopotency had been observed in urinary and CSF GAG (heparan
sulfate) measurements as well as potential disease-modifying effects in the liver and spleen.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>On August 4, 2016, the Company announced it had received
European regulatory approval by the Agencia Espanola de Medicamentos y Productos Sanitarios for its Phase 1/2 trial for ABO-102
(AAV-SGSH) to be conducted at Cruces University Hospital (Bilbao, Spain).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>On August 9, 2016, Abeona announced a collaboration with
the EB Research Partnership, EB Medical Research Foundation and Stanford University for the development of treatments for recessive
dystrophic epidermolysis bullosa (RDEB). Clinical results for the lead EB program (EB-101) were recently presented at the opening
Plenary Session of the Society for Investigative Dermatology in May 2016, and Investigators at Stanford are recruiting patients
for a Phase 2 clinical trial of EB-101 in adolescents age 13 and older to determine the effect of type VII collagen gene corrective
grafts on wound healing efficacy.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Second Quarter Summary Financial Results</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>Cash Position</I></B>: Cash, cash equivalents
and marketable securities as of June 30, 2016 were $34.3 million, compared to $37.4 million as of March 31, 2016. Net cash used
in operating activities in the Six Months Ended June 30, 2016 was $5.6 million as compared to $5.0 million in the same period
in 2015, an increase of $0.6 million.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>Revenues</I></B>: Revenues were $214 thousand
for the second quarter of 2016, compared to $282 thousand in in the second quarter of 2015. Revenues consisted of a combination
of royalties from marketed products, primarily MuGard&reg;, and recognition of deferred revenues related to upfront payments from
early license agreements.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><B><I>Loss per share</I></B>: Loss per share was $0.20
for the second quarter of 2016, compared to a loss per share of $0.16 in comparable period in 2015.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Abeona: </B><FONT STYLE="color: #26282A">Abeona Therapeutics
Inc. is a clinical stage company developing gene therapy and plasma-based therapies for severe and life-threatening rare genetic
diseases. Abeona's lead programs are ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies
for Sanfilippo syndrome (MPS IIIA and IIIB), respectively. We are also developing EB-101 (gene-corrected skin grafts) for recessive
dystrophic epidermolysis bullosa (RDEB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV-FANCC)
for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases.
In addition, Abeona is developing plasma protein therapies, including SDF Alpha&trade; (alpha-1 protease inhibitor) for inherited
COPD, using our proprietary SDF&trade; (Salt Diafiltration) ethanol-free process. For more information, visit </FONT><FONT STYLE="color: #0081F2">www.abeonatherapeutics.com</FONT><FONT STYLE="color: #26282A">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #26282A"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #26282A"><I>This
press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of
1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued
development and internationalization of our clinical programs, that we are </I></FONT><I>looking forward to advancing multiple
important new therapeutic candidates for the treatment of epidermolysis bullosa, that we plan to accelerate up to three new promising
EB product candidates toward commercialization, that encouraging signs of early biopotency had been observed in urinary and CSF
GAG (heparan sulfate) measurements as well as potential disease-modifying effects in the liver and spleen in our ABO-102 program,
<FONT STYLE="font-family: Times New Roman, Times, Serif; color: #26282A">management plans for the Company, and general business
outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in
our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop
our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial
markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on
Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations
to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances
occurring after the date of this release, whether as a result of new information, future developments or otherwise.</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Christine Berni-Silverstein<BR>
Vice President, Investor Relations<BR>
Abeona Therapeutics Inc<BR>
+1 (212)-786-6212<BR>
csilverstein@abeonatherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Andre'a Lucca<BR>
Vice President, Communications &amp; Operations<BR>
Abeona Therapeutics Inc<BR>
+1 (212)-786-6208<BR>
alucca@abeonatherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I 24# 2(  A$! Q$!_\0
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M!#=P3WD:YF$*LJCG@C-;=7&2DKHN,E)704445104444 %%%% !1110 4444
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M*RBCM-3GMTU":8F)7^SRN7*<D;@QYP?3VJMK1NGU&TA@D9D\MV:WBN/)D?D
M,#W STR.M:=II]G8!A:VT<._[Q5>6^II;NPM+]56ZMXY@IRN]<X^GI0XOEL#
MBW&QA0/+9ZI9"=-0MA-(8PLMT)TD.TG!&21TSD>E=+5*VT?3K.;SK>SA24#
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=-:9Y 78[LD=, 'I@ <=,5>HHH;N"5@HHHI#/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
